MXPA99011317A - Solid pharmaceutical dosage forms in form of a particulate dispersion - Google Patents
Solid pharmaceutical dosage forms in form of a particulate dispersionInfo
- Publication number
- MXPA99011317A MXPA99011317A MXPA/A/1999/011317A MX9911317A MXPA99011317A MX PA99011317 A MXPA99011317 A MX PA99011317A MX 9911317 A MX9911317 A MX 9911317A MX PA99011317 A MXPA99011317 A MX PA99011317A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- particles
- polymer
- peg
- hpc
- Prior art date
Links
- 239000006185 dispersion Substances 0.000 title claims abstract description 66
- 239000007787 solid Substances 0.000 title claims abstract description 21
- 239000002552 dosage form Substances 0.000 title claims description 12
- 239000003814 drug Substances 0.000 claims abstract description 78
- 229940079593 drugs Drugs 0.000 claims abstract description 77
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 62
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 61
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 37
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 36
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 35
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 20
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 17
- 239000000969 carrier Substances 0.000 claims abstract description 15
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 15
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 12
- 239000011159 matrix material Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 7
- 230000036912 Bioavailability Effects 0.000 claims abstract description 6
- 230000035514 bioavailability Effects 0.000 claims abstract description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 6
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000155 melt Substances 0.000 claims abstract description 3
- 230000001747 exhibiting Effects 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical group C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 8
- 229960001641 troglitazone Drugs 0.000 claims description 8
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 3
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical group C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 3
- 238000000605 extraction Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 41
- 239000000203 mixture Substances 0.000 description 31
- 229920001223 polyethylene glycol Polymers 0.000 description 29
- 239000002202 Polyethylene glycol Substances 0.000 description 26
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 21
- ISGUIIHZEJGUGQ-UHFFFAOYSA-N heptacosaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ISGUIIHZEJGUGQ-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 239000008363 phosphate buffer Substances 0.000 description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
- -1 cyclotazone Chemical compound 0.000 description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 13
- 238000000634 powder X-ray diffraction Methods 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 5
- 229960002155 Chlorothiazide Drugs 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000006069 physical mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010268 HPLC based assay Methods 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000035536 Oral bioavailability Effects 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 230000036220 oral bioavailability Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229960001466 Acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N Acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- VIROVYVQCGLCII-UHFFFAOYSA-N Amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 1
- 229960001301 Amobarbital Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229960003515 Bendroflumethiazide Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N Benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 Benzbromarone Drugs 0.000 description 1
- MAFMQEKGGFWBAB-UHFFFAOYSA-N Benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 description 1
- 229960003789 Benzonatate Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 229940107084 Chlorthalidone Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N Clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N Digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- MVDXXGIBARMXSA-UHFFFAOYSA-N Englitazone Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-UHFFFAOYSA-N 0.000 description 1
- 229950002375 Englitazone Drugs 0.000 description 1
- 229940083253 Ergot alkaloid peripheral vasodilators Drugs 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 Furosemide Drugs 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 229960002972 Glutethimide Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N Griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N Hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004815 Meprobamate Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N Nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 Nifedipine Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 Nitrofurantoin Drugs 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- XQYZDYMELSJDRZ-UHFFFAOYSA-N Papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 1
- 229960002695 Phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N Quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- PBCZLFBEBARBBI-UHFFFAOYSA-N Sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N Sulfametoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N Sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229940032484 Sulfisoxazole Drugs 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N Tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N Trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 Trifluoperazine Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N Trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 Trimethoprim Drugs 0.000 description 1
- 229940099270 Vasotec Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LWZFANDGMFTDAV-URHIDPGUSA-N [(2R)-2-[(3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-URHIDPGUSA-N 0.000 description 1
- IYFATESGLOUGBX-CBOZIWPYSA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O IYFATESGLOUGBX-CBOZIWPYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940051869 antimigraine Ergot alkaloids Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960003133 ergot alkaloids Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008342 pharmaceutical dispersion Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004730 sulfabenzamide Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229950006952 sulfameter Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Abstract
Solid particulate dispersions of pharmaceutical agents in a matrix of a water-soluble polymer exhibiting good aqueous dissolution enhanced bioavailability. The method of the invention utilizes water-soluble polymers such as polyvinylpyrrolidone, hydroxypropyl cellulose or hydroxypropylmethyl cellulose as carriers. The invention provides for mixing or extracting the active ingredients in solid particulate form with the polymeric carrier at a temperature at which the polymer softens, or even melts, but the drug remains solid or crystalline. The drug particules thus become coated and produce a product that is matrix coated, i.e. a particulate dispersion.
Description
FORMS OF SOLID PHARMACEUTICAL DOSES IN THE FORM OF PARTICLE DISPERSION
FIELD OF THE INVENTION This invention relates to orally bioavailable dosage forms of pharmaceutical agents of low water solubility.
BACKGROUND OF THE INVENTION Many pharmaceutical agents are chemical structures so complex that they are insoluble or only very poorly soluble in water. The foregoing results in null or sparse dissolution from conventional dosage forms designed for oral administration. The low dissolution rates result in no or low bioavailability of the active chemical substance, which makes the oral supply ineffective therapeutically, and parenteral administration is needed to achieve a beneficial therapeutic result. Drug products that are limited to parenteral delivery lead to higher health care costs, due to higher manufacturing costs, more expensive accessories required for delivery, and in many cases hospitalization of the patient to ensure proper dosing (eg, sterile intravenous delivery).
Poorly water soluble drugs that undergo gastrointestinal absorption limited to the type of solution usually show greater bioavailability when the type of solution is improved. To improve the dissolution property. and potentially the bioavailability of drugs that are poorly soluble in water, many strategies and methods have been proposed and used, including the reduction of particle size, selection of salts, formation of molecular complexes and solid dispersions, and the use of polymorphic forms metastable, cosolvent and surface active agents. Of these methods, the use of surface active agents is mainly to improve the wetting ability of drugs that are poorly soluble in water, which eventually results in the improvement of the type of solution.
We have now discovered a method for producing solid particulate dosage forms of poorly water-soluble pharmaceutical agents, which makes them ideally suited for oral administration, and which provides an improved type of water dissolution and thus an oral bioavailability. improved The method of this invention uses water-soluble polymers such as polyvinylpyrrolidone, hydroxypropyl cellulose or methylcellulose hydroxypropyl as carriers. The use of these water-soluble carriers improves the wetting ability of crystalline pharmaceutical agents which are poorly soluble in water, thus improving the type of solution after administration, which ultimately results in better bioavailability and therapeutic result. The invention provides the mixing or extrusion of the active ingredients in the form of solid particles with the polymeric carrier at a temperature at which the polymer softens, or even melts, but in which the drug remains solid or crystalline. The particles of the drug are thus covered and produce a product that is covered by the matrix, that is, a dispersion of particles.
SUMMARY OF THE INVENTION This invention provides solid dosage forms of pharmaceutical agents with poor water solubility. More particularly, the invention is a pharmaceutical composition in the form of a solid particle dispersion of a pharmaceutical ingredient in dispersed particles in a matrix of a water-soluble polymer such as polyvinylpyrrolidone, hydroxypropyl cellulose or methylcellulose hydroxypropyl.
In a preferred example, the particulate pharmaceutical ingredient is dispersed in a water soluble polymer in a weight ratio of from about 10% to about 90% active ingredient for about 90% to about 10% of the polymer. A preferred formulation comprises about 20% to about 80% of the active ingredient and about 80% to about 20% of the polymer. The most preferred composition comprises about 50% to about 80% of the active ingredient and about 20% to 50% of the polymer or other excipients.
In another preferred specimen, the pharmaceutical ingredient is dispersed in hydroxypropyl cellulose or methylcellulose hydroxypropyl. Especially preferred compositions comprise from 40% to 80% by weight of the active ingredient. The precise ratio of the polymer to the drug in the matrix is dictated by the size of the particle, and thus the surface area of the crystalline drug substance. Other conventional excipients such as glycerin, propylene glycol, Tween, salts of stearic acids, polyvinyl pyrrolidones and the like can be added.
In a particularly preferred example, the poorly soluble pharmaceutical agent used is chosen from the class known as gliotazones. Glitazones are antidiabetic agents of thiazolidinedione such as troglitazone, cyclotazone, pioglitazone, englitazone and BRL 49653.
The most preferred composition of the invention is a solid dispersion of troglitazone in hydroxypropyl cellulose.
DETAILED DESCRIPTION OF THE INVENTION The compositions provided by this invention are dispersions of pharmaceutical agent particles barely soluble in a water soluble polymer such as hydroxypropyl cellulose or methylcellulose hydroxypropyl.
Hydroxypropyl cellulose is also known as cellulose 2-hydroxypropyl ester, oxypropylated cellulose and HPC. It is a non-ionic water soluble cellulose ether that exists as an almost white powder. While hydroxypropyl cellulose is soluble in many polar organic solvents, it readily precipitates from water at about 40 ° C. It is a thermoplastic material that has been used in the pharmaceutical field as an emulsifier, stabilizer, shake aid, protective colloid, as well as a film former or thickener in foods.
The methylcellulose hydroxymethyl is 2-hydroxypropyl methyl ether cellulose or HPMC. It is a nonionic water soluble ether of methylcellulose, which is insoluble in hot water but dissolves slowly in cold water. It is more soluble than methylcellulose, and has been used extensively as an emulsifier, stabilizer, suspending agent, tablet excipient, and most notably as an ophthalmic lubricant. It is sold commercially as Ultra Tears, Tearisol and Goniosol.
The compositions of this invention utilize barely soluble pharmaceutical agents. The term "barely soluble pharmaceutical agent" means any solid or crystalline drug substance that will dissolve in from 30 to 100 grams of water at 25 ° C. Numerous drug substances are "barely soluble pharmaceutical agents" as used herein, and can be used to make the particle dispersions of this invention. As noted above, a preferred group of such agents are glitazones, especially troglitazone, also known as "Cl-991". Glitazones are described in more detail in U.S. Patent No. 5,478,852, which is incorporated herein by reference. Other agents that may be employed include antibiotics, such as cephalosporins and penicillins, fluoroquinolinones such as clinafloxacin, naphthyridinones such as Cl-990 and compounds of the arithromycin amine type. Antidepressant agents such as chlorothiazide and ACE inhibitors (quinapril, vasotec) can be formulated according to this invention. Anticarcinogenic agents such as methotrexate, suramin and vinca alkaloids can be used.
Other pharmaceuticals that can be formulated as particle dispersions include, but are not limited to acetohexamide, ajamaline, amylobarbitone, bendrofluazide, benzbromarone, benzonatate, benzibenzoate, betamethasone, chloramphenicol, chlorpropamide, chlorthalidone, clofibrate, corticosteroids, diazepam, dicumerol, digitoxin , dihydroxypropylteophylline, ergot alkaloids, etotine, frusemide, glutethimide, griseofulvin, hydrochlorothiazide, hydrocortisone, hydroflumethiazide, hydroquinone, hydroxyalkyloxanthines, indomethacin, isoxuprin hydrochloride, ketoprofen, quelin, meprobamate, nabilone, nicotainamide, nifedipine, nitrofurantoin, novalgin, nystatin, papaverine, paracetamol, phenylbutazone, phenobarbitone, prednisolone, prednisone, primadone, reserpine, romglizone, pill acid, spiranolactone, sulfabenzamide, sulfadiamadine, sulfamethoxydiazine, sulfamerzain, succinylsulfatiazole, sulfametiazole, sulfamethoxazole, sulfathiazole, sulfisoxazole, testosterone, tolazoline, tolbutamide, trifluoperazine, trimethoprim and other water soluble drugs.
Any number of water-soluble polymers can be used as a carrier for the dispersion of particles. All that is required is that the polymer be able to soften or melt at a temperature that does not melt the solid drug substance, so that the matrix covering the particulate drug substance can be formed. The polymer must also be sufficiently soluble in water to allow the dispersion of the dispersion of particles at a rate that provides the desired oral bioavailability and the resulting therapeutic benefit. Typical polymers to be employed include polyvinylpyrrolidone (PVP), polyethylene oxides, pregelatinized starch, methylcellulose, hydroxymethylcellulose, polyvinyl alcohol, sodium alginate, sodium carboxymethylcellulose, lecithin, tweens, maltodextrin, poloxamer, sodium lauryl sulfate, polyethylene glycol (PEG). , acetate vinyl copolymer, Eudragit® acrylic polymers, E-100 and mixtures thereof. The carrier chosen obviously depends on the drug to be dispersed but usually, the carrier chosen must be pharmaically inert and chemically compatible with the drug in the solid state. They should not form highly bound complexes with a strong constant association and more importantly they should be freely soluble in water with rapid intrinsic dissolution properties.
Another polymer chosen in most dispersions is PVP, which is a free-flowing amorphous powder that is soluble at the same time in water and in organic solvents. It is hygroscopic in nature and compatible with a wide range of hydrophilic and hydrophobic resins. Another preferred carrier is a high molecular weight polyethylene glycol such as PEG 6000, which is a condensation polymer of ethylene glycol. The polyethylene glycols are generally from a liquid to a clear, colorless, odorless, viscous waxy solid that is soluble or miscible in water.
The surprising and unexpected results of the present invention is the creation of a pharmaical dispersion of solid particles composed of the aforementioned water-insoluble drugs and carriers without the need to use aqueous or organic solvents. In another example, the addition of a plasticizer / solubilizer during the mixing of the particulate drug and the water soluble polymer results in a chemical environment that readily lends itself to the formation of particle dispersion.
Suitable plasticizers / solubilizers useful in the practice of the present invention include polyethylene glycols of low molecular weight such as PEG 200, PEG 300, PEG 400, and PEG 600. Other suitable plasticizers include propylene glycol, glycerin, triacetin and triethyl citrate. Optionally, an active tense agent such as Tween
80 can be added to facilitate wetting within the formulation.
The water-insoluble drug of interest can be ground first to the desired particle size, usually from about 1 miera to 20 micras. It is then mixed with the polymeric carrier using any suitable mixer or mixer in a drug / carrier ratio of from about 1: 9 to about 5: 1, respectively, based on a percentage basis by weight. Preferably, the drug / carrier ratio will be from about 3: 1 to about 1: 3, respectively. The mixture is then transferred to a mixer, for example a low or high power mixer or a fluid bed granulator, and additional excipients can be added, for example a plasticizer such as PEG 400, which can be dissolved in water with an agent surfactant as is tween 80, if desired. Other surfactants include Tween 20 and 60, Span 20, Span 40, pluronics, polyoxyethylene sorbitol esters, monoglycerides, polyoxyethylene acids, polyoxyethylene alcohols and mixtures thereof. Once all the ingredients are sufficiently dissolved or suspended, the solution is sprayed onto the powder mix in the fluid bed granulator under specific conditions. The mix can also be granulated in a low or high power mixer, dry and mold to produce the granulated product. The resulting granulation is transferred to a container and fed into a high intensity mixer such as a twin screw extruder with at least one, and preferably more than one heating zone. The mixture is then extruded at appropriate temperatures depending on the heat stability of the drug, until a dispersion of particles is collected as an extract, which is then transferred to a barrel to be milled. The pharmaceutical dispersion of ground particles can then be ground into a powdery mass, and can be further mixed with other excipients before their encapsulation or being pressed into tablets. The final dosage form can optionally be covered with a film such as methylcellulose hydroxypropyl, if desired.
In a preferred example, the particle dispersions of the invention are prepared by melt extrusion of a pharmaceutical agent and about 10 to 90 percent by weight of a polymer such as HPC. The molten extrusion is carried out by mixing the ingredients until uniformity is reached at a temperature of about 50 ° C to about 200 ° C, the temperature that is high enough to melt or soften the polymer, but not high enough to melt the particles of the drug. The melted or softened mixture is passed through a commercial twin screw extruder. The resulting extract can be used directly, or can be further processed, by example by grinding or pulverizing to the desired consistency, and further mixed with conventional carriers such as starch, sucrose, talc and the like, and can be pressed into tablets or encapsulated. The final dosage forms will usually contain about 1 mg to about 1000 mg of the active ingredient, and more typically about 300 mg to about 800 mg.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 is the X-ray powder diffraction of crude troglitazone (Cl-991), where: A) Diffraction intensity - counts per second (cps); and B) Diffraction angle (° 2 (H)).
Figure 2 is the X-ray powder diffraction of the dispersion of Cl-991 particles in PEG-8000 and PVP in a weight ratio of 80: 10:10:10, wherein: A) Diffraction intensity - counts per second (cps); and B) Diffraction angle (° 2 (H)).
Figure 3 is the powder X-ray diffraction of the dispersion of Cl-991 particles in PEG-8000 and HPC in a weight ratio of 80:10: 10, where: A) Diffraction intensity - counts per second (cps); and B) Diffraction angle (° 2 (H)).
Figure 4 is the X-ray powder diffraction of the dispersion of Cl-991 particles in PEG-8000 and PVP in a weight ratio of 75:10:15, where: A) Diffraction intensity - counts per second (cps); and B) Diffraction angle (° 2 H).
Figure 5 is the powder X-ray diffraction of the dispersion of Cl-991 particles in PEG-8000 and HPC in the weight ratio of 75:10:15, where: A) Diffraction intensity - counts per second (cps); and B) Diffraction angle (° 2 H).
Figure 6 is the X-ray powder diffraction of the dispersion of Cl-991 particles in PEG-8000 and HPC in the weight ratio of 75: 5: 20, where: A)
Diffraction intensity - counts per second (cps); and B) Diffraction angle (° 2 (H :)).
Figure 7 is the X-ray powder diffraction of the dispersion of Cl-991 particles in PEG-8000 and HPC in the weight ratio of 75:25, where: A) Diffraction intensity - counts per second (cps) ); and B) Diffraction angle (° 2 (H)).
Figure 8 is a comparison of dissolution profiles at pH 8 for various dispersion formulations of Cl-991 particles, wherein: A) percentage of drug dissolved; B) Cl-991 PD [drug / HPC (75/25)]; C) Cl-991 PD [drug / PEG / HPC (75/5/20)]; D) Cl-991 PD [drug / PEG / HPC (75/10/15)]; E) Cl-991 PD [drug / PEG / HPC (80/10/10)]; F) Mixture [drug / HPC (75/25)]; G) Cl-991 pure; and H) time (minutes).
Figure 9 is a comparison of dissolution profiles at pH 9 for various dispersion formulations of Cl-991 particles, wherein: A) percentage of drug dissolved; B) Cl-991 PD [drug / HPC (75/25)]; C) Cl-991 PD [drug / PEG / HPC (75/5/20)]; D) Cl-991 PD [drug / PEG / HPC (75/10/15)]; E) Cl-991 PD [drug / PEG / HPC (80/10/10)]; F) Mixture [drug / HPC (75/25)]; G) Cl-991 pure; and H) time (minutes).
Figure 10 is a comparison of dissolution profiles at pH 8 for various dispersion formulations of Cl-991 particles in PVP, wherein: A) percentage of drug dissolved; B) Cl-991 PD [drug / PEG / PVP (75/10/15)]; C) Cl-991 PD [drug /
PEG / PVP (80/10/10)]; D) Cl-991 pure; and E) time (minutes).
Figure 11 is a comparison of dissolution profiles at pH 9 for various dispersion formulations of Cl-991 particles in PVP, wherein: A) percentage of drug dissolved; B) Cl-991 PD [drug / PEG / PVP (75/10/15)]; C) Cl-991 PD [drug / PEG / PVP (80/10/10)]; D) Cl-991 pure; and E) time (minutes).
Figure 12 is a comparison of dissolution profiles at pH 8 for various dispersion formulations of Cl-991 particles in PVP, wherein: A) percentage of drug dissolved; B) Cl-991 PD [drug / PEG / HPC (75/10/15)]; C) Cl-991 PD [drug /
PEG / HPC (80/10/10)]; D) Cl-991 PD [drug / PEG / PVP (75/10/15)]; E) Cl - 991 PD
[drug / PEG / PVP (80/10/10)]; and F) time (minutes).
The following detailed examples further illustrate the present invention. The examples are illustrative only and should not be construed as limiting the invention in any respect.
EXAMPLE 1 Dispersion of Chlorotiazide Particles A mixture of 54 g of chlorothiazide and 6 g of hydroxypropyl cellulose were mixed until unm at 24 ° C using a mortar and pedestal. The mixture was transferred to a rotary mixing vessel and heated to 150 ° C, and stirred at 50 rpm. The moment remained at 2000 meter - grams. The mixture was frozen and after cooling to 24 ° C, it was solid and unm. The product pulverized and ground, and pressed into tablets. Each tablet was a solid particulate formulation of chlorothiazide.
EXAMPLE 2 A mixture of 54 g of chlorothiazide and 6 g of hydroxypropyl cellulose were mixed until unm at 24 ° C in a mortar and pedestal. The mixture was added to a rotary mixing vessel and stirred for 1 hour at 70 ° C at 50 rpm. The mixture was cooled, ground and pressed into tablets which were dispersions of solid chlorothiazide particles.
EXAMPLE 3 Troglitazone (Cl-991), a new drug developed for the treatment of non-insulin dependent diabetes, is a drug practically insoluble in water of the gastrointestinal range pH 1.0 to 7.5. To date, Cl-991 has been prepared as a solid dispersion, in which the crystalline drug substance is converted to the amorphous form by hot melt extrusion methods, to improve its rate of dissolution and its oral biodiposibility. In this study, Cl-991 was used as a model drug to test whether the type of dissolution of poorly water-soluble drugs could be improved by the approach of forming a dispersion of particles in a matrix of a water-soluble polymer.
Troglitazone (Cl-991) Materials The crude drug Cl-991 (batch XX020195) and the water-soluble excipients chosen HPC, PVP K28-32 and PEG-8000, were all obtained from Centralized Raw Materials (Morris Plains, New Jersey) . The chemicals used to prepare the dissolution medium, including hydrogen disodium phosphate (Na2HPO), dipotassium hydrogen phosphate (K2HPO4) and 85% phosphoric acid (H3PO4), were obtained from J.T. Baker Co. (Phillisburg, New Jersey) while sodium lauryl sulfate (SLS) was obtained from Centralized raw Materials.
Preparation of Cl-991 Particle Dispersions (PD) Cl-991 particle dispersions were prepared by the mixing vessel method. The appropriate weights of Cl-991 and the excipients were placed in a screw capped bottle and mixed by a turbula mixer (Glenn Mills Co. Maywood, New Jersey) for 15 minutes to give powder mixtures (or physical mixtures). About 65 g of the powder mixtures were then mixed in a Brabender double screw mixing vessel (C. W. Brabender Instruments, South Hackensac, New Jersey) at 110 ° C or 130 ° C for 5 minutes. The resulting products (Cl-991 PD) were collected, ground and divided. The samples that had particle size between 80- and 100-mesh were used for the dissolution study and other tests.
HPLC Assay of Cl-991 Particle Dispersions The HPLC method used for the Cl-991 assay was adopted from RTD-0991 -TAC-5 (pages 5-12). HPLC analysis was carried out on Hewlett-Packard 1090 HPLC system with a Hewlett-Packard 1050 absorbance detector and a Cte Alltech Hypersil column (4.5 x 100 mm, 3 μm). The mobile phase consisted of a 50:50 mixture (% v / v) of pH 3 (0.05 M) of regulator triethylamine and acetonitrile. The flow rate was 1-5 ml / minute, the wavelength of the UV detection was 225 nm, the injection volume was 20 μl and the execution time was 15 minutes. The retention time for the maximum of Cl-991 was found to be approximately 5.6 minutes. The acquisition and integration of data was carried out with a computer program
Hewlett-Packard ChemStation (Rev. A.02.00).
Characterization of Crystallinity The Crystallinity of the dispersions of Cl - 991 particles was characterized using X - ray powder diffractometry. Diffractometry patterns of X - ray powder were recorded by using a Rigaku Geiger - Flex X - ray diffractometer with radiation of Cu-Ka filtered in Ni (? = 1.5418 Á) during the interval 4 - 40 2T. In some cases, optical polarization microscopy was used to confirm the results obtained with X-ray powder diffraction. Microscopic investigation was carried out in a Leitz Labolux 12 polarization optical microscope equipped with a Polaroid camera.
Dissolution Studies Preparation of Dissolution Medium pH 8 (0.1 M. Phosphate Regulator with 0.5% Content (g / mL) SLS Phosphate solution (0.1 M) was prepared by dissolving a calculated amount of Na2HPO4 in USP water. The pH value of the phosphate solution (0.1 M) was then adjusted to 8.0 ± 0.02 by 85% phosphoric acid to give a phosphate buffer (0.1 M) with pH 8 .. An appropriate amount of SLS is added and dissolved in the phosphate buffer (0.1 M) of pH 8 to give the phosphate buffer (0.1 M) pH 8 containing
0. 5% / g / mL) of SLS.
Phosphate Regulator (0.05 M) pH 9 Phosphate solution (0.05 M) was prepared by mixing 1: 1 of the aqueous solutions of (0.025 M) Na2HPO and (0.025 M) K2HPO4. The pH value of the phosphate solution (0.05 m) was then adjusted to 9.0 ± 0.02 by 85% phosphoric acid to give the phosphate buffer with pH 9 (0.05 M).
Dissolution tests The dissolution studies were carried out in 900 ml of dissolution medium maintained at 37 ° C, using USP II devices (Dissolution System Distek 2100 and North Brunswick, New Jersey) at 75 rpm of blade speed. After dispersing a sample containing 100 Cl-991 in the dissolution medium, about 10 ml of solutions were sampled periodically and filtered with 0.45 μm Gelman Nylon Acrodisc filters to give clear filtrations (discard the first 2 ml of filtered out). The amount of the drug dissolved in the dissolution medium was determined by UV spectrometry a? = 284 nm. The interference of the excipients was not observed during the analysis. The experiments were run in duplicate, and the results were averaged.
RESULTS AND DISCUSSION Preparation and HPLC Assay of Cl-991 Particle Dispersions Depending on the sizes of the samples, the particle dispersion could be prepared by the method of the mixing or extrusion vessel. To minimize the amount of crude Cl - 991 drug used, dispersions of Cl - 991 particles were used using the mixing vessel method in this exploratory study. Since the melting range of Cl - 991 has been reported from 165 ° C to 175 ° C, the temperature applied to the mixing processes should be lower than the melting temperature of CI - 991 to prevent the drug from melting but it must be high enough to soften or melt the water-soluble excipients used. By using this method of mixing vessel, six dispersions of Cl-991 particles, namely Cl-991 / PEG -8000 / PVP (80:10:10), Cl-991 / PEG-8000 HPC (80: 10:10), Cl-991 / PEG-8000 / PVP (75: 0: 25), Cl-991 / PEG-8000 / HPC (75:10:15), Cl-991 / PEG-8000 / HPC (75 : 5: 20) and Cl-991 / HPC (75:25) PD, were prepared at 110 ° C or 130 ° C [Table 1].
To investigate the chemical stability of Cl-991 during the mixing process, the six dispersions of Cl-991 particles were tested using HPLC methods. As presented in Table 1, the contents of the drug as measured in the six dispersions of Cl-991 particles agreed well with those of the theoretical values, suggesting that Cl-991 did not decompose significantly as that the drug was mixed with PEG, HPC and / or PVP at 110 ° C or 130 ° C.
TABLE 1. Preparation and HPLC Assay of Various Particle Dispersions of Cl-991 / Polymer (PD)
X-ray Powder Diffraction Study Since the mixing temperature (110 or 130 ° C) is well below the melting range of Cl-991 (165 - 175 ° C), the drug is not expected to melt or convert amorphous during the formation of the Cl-991 particle dispersion. The X-ray powder diffraction patterns of the crude Cl-991 drug and the six particulates of Cl-991 are illustrated in Figure 1 and in the Figures from 2 to 7, respectively. The crystalline properties of the crude drug are characterized by several major diffraction maxima near 5.5, 11.8, 17.6, 19.6 and 23.7 ° (2T), in the diffractome [Figure 1]. For Cl-991 / PEG / PVP and Cl-991 / PEG / HPC (80:10:10) PD that were prepared at 110 ° C, their X-ray diffraction patterns (Figures 2 - 3) are almost identical to those of the crude drug Cl-991. Except for a few slight diffraction maxima in the region of 8.5 - 0.2 2T (, most of the identifiable diffraction maxima of Cl - 991 were observed in the diffractograms of Cl - 991 / PEG / PVP (75:10:15) , Cl-991 / PEG / HPC (75:10:15),
Cl-991 / PEG / HPC (75: 5: 20) and Cl-991 / HPC (75:25) PD [Figures 4 to 7], which were prepared at 130 ° C. Figures 1 to 7 also revealed that the dispersions of Cl-991 particles, especially those prepared at 130 ° C, exhibited higher diffraction maxima than the crude Cl-991 drug. These data may indicate that the crude crystalline drug has been partially converted to the amorphous form and / or interacts with the polymers used during the mixing process at elevated temperatures for the preparation of the dispersions of Cl-991 particles.
Dissolution Studies The dissolution behaviors of the dispersions of Cl - 991 / polymer particles were studied in two different dissolution media, namely phosphate buffer pH 8 (0.1 M) with 0.5% SLS content and phosphate buffer pH 9 (0.05 M). The dissolution profiles of several dispersions of particles Cl-991 / PEG-8000 / HPC in phosphate buffer pH 8 (0.1 M) with content of 5% of SLS and in phosphate buffer pH 9 (0.05 M) are illustrated in the Figures 8 and 9, respectively. The dissolution profiles of the crude drug Cl-991 (or pure Cl-991) and the physical mixture of Cl-991 / HPC (75:25) are also illustrated in Figures 8 and 9 for comparison.
It is clearly indicated that the four dispersions of Cl-991 particles exhibit a type and a larger amount of Cl-991 solution than the pure drug and the physical mixture in these two dissolution media. The improvement in the Cl - 991 dissolution types would be mainly due to the increase in wettability of Cl - 991, since the drug has been covered with HPC and / or PEG - 8000 (water - soluble polymers) during the formation of the dispersion. of Cl-991 particles. In addition to the coverage of water-soluble polymers, the type of Cl-991 solution could be improved by reducing the size of the particles since the drug can be finely dispersed in the matrix of the particles. polymers during the mixing process.
Of the four particle dispersions studied, Cl-991 / HPC (75:25) PD exhibited the highest type of solution. The above is understandable because this dispersion of particles has the highest concentration of HPC, in which the resulting particles could have the best wettability of the four dispersions of Cl-991 / HPC particles. Cl - 991 / HPC (75:25) PD produced a 12-fold higher initial dissolution type (computed during the first five minutes of dissolution) in phosphate buffer pH (0.1 M) with 0.5% SLS content than Cl - 991 pure (Table 2 and Figure 8). In phosphate buffer 9 (0.05 M), Cl-991 / HPC (75:25) PD also produced a much higher type of solution than pure Cl-991 (Table 2 and Figure 9). After 15 minutes, this dispersion of particles produced a 7-fold type of solution in phosphate buffer pH 8 (0.1 M) with a content of 5% SLS and a type of solution 20 many times higher in phosphate buffer pH 9 (0.05) M) than the pure drug.
The dissolution profiles of Cl-991 / PEG-8000 / PVP (80:10:10) and (75:10:25) in phosphate buffer pH 8 (0.1 M) with content of 5% SLS and in regulator of phosphate pH 8 (0.05 M) are illustrated in Figures 10 and 11, respectively. As with the Cl-991 / PEG-8000 / HPC particle dispersions, these two Cl-991 / PEG / PVP PD exhibited faster drug release profiles than pure Cl-991. Again, Cl-991 / PEG / PVP PD with higher concentration of PVP resulted in faster release of the drug from the particle dispersions (Figures 10 and 11). These dissolution studies show that Cl - 991 / PEG / HPC (80:10:10) and (75:10:15) PD have higher dissolution rates than the corresponding Cl - 991 / PEG / PVP PD, especially in the regulator phosphate pH 8 (0.1 M) with 5% SLS content (Figure 12). These obtained data may indicate that HPC is a better water-soluble polymer than PVP to improve the type of dissolution of the drug for the dispersion of Cl-991 particles. The reason for these differences is not clear yet; however, it may be due to the different physical and chemical properties between HPC and PVP, such as glass transition temperature (Tg), rheological behavior at elevated temperatures, and / or drug / polymer interactions. However, this study clearly showed that the type of dissolution of a drug poorly soluble in water, Cl-991, can be improved by the formation of a particle dispersion, in which the drug was covered with (or finely dispersed in ) the water-soluble excipients, such as HPC and PVP, with high drug loads.
TABLE 2. Dissolution of several particle dispersions of Cl-991 / polymer (PD), pure Cl-991, and physical mixture of Cl-991 / HPC (75:25) in Two Different Dissolution Means
CONCLUSION Six dispersions of Cl-991 / polymer particles (PD), namely Cl-991 / PEG-8000 / PVP (80:10:10), Cl-991 / PEG-8000 / HPC (80:10:10) , Cl-991 / PEG-8000 / PVP (75: 0: 25), Cl-991 / PEG-8000 / HPC (75:10:15), Cl-991 / PEG-8000 / HPC (75: 5: 20 ) and Cl-991 / HPC (75:25) PD were prepared by the mixing vessel method at 110 ° C or 130 ° C. The HPLC assay revealed that the drug contents of these particle dispersions are almost identical to those of the theoretical values, suggesting that Cl-991 did not undergo any significant decomposition during the mixing process at 110 ° C or 130 ° C. X-ray powder diffraction studies suggested that the drug substance in dispersions of Cl-991 particles is almost as it existed in the crystalline state. The six dispersions of Cl-991 particles exhibited all drug release profiles faster than pure Cl-991 and the physical mixture Cl-991 / HPC / (75:25) in phosphate buffer pH 8 (0.1 M) with content of 0.5% SLS and phosphate buffer pH 9 (0.05)
M) The improvement in the type of dissolution of the drug can be mainly due to the increase in wettability and / or the reduction of the size of the Cl-991 particles as the drug was covered with highly water soluble polymers such as HPC and PVP during the extrusion process. It was found that HPC appears to be a better water-soluble polymer than PVP to improve the type of Cl-991 dissolution of the particle dispersion. This study showed that the type of dissolution of large doses of poorly water soluble drugs such as Cl - 991 could be improved by improving the wettability of the drugs due to the formation of particle dispersions.
Claims (7)
- CLAIMS: 1. A solid form of pharmaceutical particle dosage suitable for oral delivery comprising a particulate pharmaceutical agent barely soluble in dispersed water through a matrix composed of a water soluble polymer.
- 2. A dosage form of Claim 1 wherein the pharmaceutical agent is glitazone.
- 3. A dosage form of Claim 2 wherein the glitazone is troglitazone.
- 4. A dosage form of Claim 2 wherein the glitazone is BRL 49653.
- 5. A dosage form of Claim 1 wherein the polymer is hydroxypropyl cellulose.
- 6. A dosage form of Claim 1 wherein the polymer is methylcellulose hydroxypropyl.
- 7. A dosage form of Claim 1 wherein the polymer is polyvinyl pyrrolidone. EXTRACT OF THE INVENTION Solid particle dispersions of pharmaceutical agents in a matrix of a water soluble polymer exhibiting good bioavailability enhanced by aqueous solution. The method of the invention uses water soluble polymers such as polyvinyl pyrrolidone, hydroxypropyl cellulose or hydroxypropylmethyl cellulose as carriers. The invention provides for the mixing or extraction of the active ingredients in the form of solid particles with the polymeric carrier at a temperature at which the polymer softens, or even melts, but the drug remains solid or crystalline. The particles of the drug are thus covered and produce a product that is covered by the matrix, that is, a dispersion of particles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US056195 | 1993-05-03 | ||
US60/056195 | 1997-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99011317A true MXPA99011317A (en) | 2000-09-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2292586C (en) | Solid pharmaceutical dosage forms in form of a particulate dispersion | |
JP3722293B2 (en) | Novel pharmaceutical solid dispersion | |
TWI389691B (en) | Solid pharmaceutical dosage forms which can be administered orally and have rapid release of active ingredient | |
CA2477890C (en) | Immediate release pharmaceutical granule compositions and a continuous process for making them | |
JP5610165B2 (en) | Nateglinide-containing preparation | |
HU228849B1 (en) | Suspension of hydrophilic polimer solution containing fenofibrate | |
EP1487416A2 (en) | Drug microparticles | |
JPS63165318A (en) | Light-stable nifedipin concentrate and manufacture | |
KR101730865B1 (en) | Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof | |
JPH031288B2 (en) | ||
MXPA99011317A (en) | Solid pharmaceutical dosage forms in form of a particulate dispersion | |
JP6072705B2 (en) | Solid dispersion formulation | |
TWI436765B (en) | Pharmaceutical composition for treating hcv infections | |
US20050215455A1 (en) | Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them | |
Imai et al. | Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin | |
WO2024024938A1 (en) | Delamanid-containing solid dispersion | |
JP2813792B2 (en) | Preparation for oral administration of irsogladine maleate and its production method | |
EP3666256A1 (en) | Pharmaceutical composition for solid dosage forms | |
US20180117159A1 (en) | Method for producing solid formulations with improved dissolution by annealing with an adjuvant | |
JPH03169814A (en) | Production of long-acting nifedipine formulation | |
CN111920804A (en) | Canagliflozin solid dispersion, preparation method and application thereof | |
JP2007131587A (en) | Pharmaceutical composition comprising quinoline derivative as active ingredient and method for producing the same | |
Verma et al. | Available Online Through Review Article www. ijptonline. com |